Last updated on November 2018

Study Evaluating Efficacy and Safety of PF-04965842 in Subjects Aged 12 Years And Older With Moderate to Severe Atopic Dermatitis


Brief description of study

B7451013 is a Phase 3 study to evaluate PF-04965842 in patients aged 12 years and older with a minimum body weight of 40 kg who have moderate to severe atopic dermatitis. The efficacy and safety of two dosage strengths of PF-04965842, 100 mg and 200 mg taken orally once daily, will be evaluated relative to placebo over 12 weeks of study participation. Eligible patients will have an option to enter a long-term extension study after completing 12 weeks of treatment.

Clinical Study Identifier: NCT03575871

Contact Investigators or Research Sites near you

Start Over

Pfizer CT.gov Call Center

Yoshioka Dermatology Clinic
Neyagawa, Japan
0.31miles
  Connect »